Thermo Fisher Scientific Human IGF-BP2 Recombinant Protein, PeproTech

Applications

Tested Dilution

Publications

Functional Assay (Functional)

Assay-dependent

-

In vitro Assay (IV)

-

View 5 publications 5 publications

Product Specifications

Species

Human

Published species

Human

Expression System

Insect cells

Amino acid sequence

EVLFRCPPCT PERLAACGPP PVAPPAAVAA VAGGARMPCA ELVREPGCGC CSVCARLEGE ACQVYTPRCG QGLRCYPHPG SELPLQALVM GEGTCEKRRD AEYGASPEQV ADNGDDHSEG GLVENHVDST MNMLGGGGSA GRKPLKSGMK ELAVFREKVT EQHRQMGKGG KHHLGLEEPK KLRPPPARTP CQQELDQVLE RISTMRLPDE RGPLEHLYSL HIPNCDKHGL YNLKQCKMSL NGQRGECWCV NPNTGKLIQG APTIRGDPEC HLFYNEQQEA RGVHTQRMQ

Molecular weight

31.5 kDa

Class

Recombinant

Type

Protein

Purity

≥ 98% by SDS-PAGE gel and HPLC analyses.

Endotoxin concentration

<1 EU/µg

Activity

Determined by its ability to inhibit IGF-I induced proliferation of FDC-P1 cells.

Conjugate

Unconjugated Unconjugated Unconjugated

Form

Lyophilized

Purification

purified

Contains

no preservative

Storage conditions

-20°C

Product Specific Information

350-06B-1MG will be provided as 2 x 500 µg (350-06B-500UG).

Recombinant Human IGF-BP2 is a 31.5 kDa protein consisting of 289 amino acid residues including the IGF-BP domain and thyroglobulin type-I domain.

This product is shipped at ambient temperature. For storage, handling and reconstitution information, please see the lot-specific Certificate of Analysis

Target Information

IGFBP2 (insulin-like growth factor binding protein 2) is a member of the ISGBP family which bind various IGFs. IGFBP2 is overexpressed in a wide spectrum of cancers, including glioma, prostate cancer, synovial sarcoma, neuroblastoma, colon cancer, adrenocortical cancer, lung cancer, Wilms` tumor, and hepatoblastoma. The overexpression of IGFBP2 also correlates with the aggressiveness of some tumors. IGFBP2 activates the expression of matrix metalloprotease 2, which contributes to cell invasiveness.

For Research Use Only. Not for use in diagnostic procedures. Not for resale without express authorization.